GSK, Pfizer pay U.S. doctors $262M

Following up Merck's doctor-payment disclosures, Pfizer and GlaxoSmithKline posted their numbers. And perhaps befitting to the world's largest drugmaker, Pfizer spent the most: $177 million was doled out to doctors in support for clinical trials and speaking fees. GSK's payments were slightly less than half that, at a total of $85 million for trials and speaking.

For Pfizer, the lion's share went to research; $108 million of its total spending supported clinical trials and related work. A chunk of the rest went to doctors for speaking on behalf of the company. Some 4,600 physicians collected a total of $34.4 million, or $7,400 on average. Then there was $18 million in free meals, $8.9 million in advisory fees (paid to 1,400 doctors), $5.8 million for travel, and $1.7 million for education.

GSK's research spending was $28.5 million, paid to various institutions working on 127 different studies with 595 lead researchers. The remaining $56.8 million went to 5,331 doctors and other healthcare professionals, for speaking and advisory work. That's about $10,600 on average. GSK said it lowered the maximum payment for any one doctor to $100,000 from $150,000, and only one doctor received the maximum.

Just for comparison's sake, let's review Merck's numbers. The company spent $20.4 million on payments to 2,088 U.S. doctors, an average of $9,770. Remember, however, that Merck's 2010 total does not include the Schering-Plough side of the business. And, note that Merck and Glaxo have posted their numbers voluntarily, while Pfizer is required to disclose payments under its off-label marketing settlement with the U.S. Justice Department.

- read the Reuters news
- get more from the Wall Street Journal
- see the Telegraph story
- check out the Philadelphia Inquirer's take

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.